FDA Approves Novel Sickle Cell Disease Treatment

December 3, 2019

FDA Approves Novel Sickle Cell Disease Treatment

The FDA granted accelerated approval to Oxbryta (voxelotor), a novel inhibitor of deoxygenated sickle hemoglobin polymerization, the central abnormality in patients with sickle cell disease.The Accelerated Approval pathway enables the FDA to approve drugs for serious conditions based on results showing it is likely to provide clinical benefits to patients. Yourway has extensive experience expediting clinical trials to take advantage of fast-tracked approval pathways.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

GCSG 2026 European Knowledge Forum

October 14-15, 2026
Rome, Italy

Schedule a Meeting

Media

Articles

Your Clinical Trial Has 99 Problems. Logistics Shouldn’t Be One.

Open chat

Hello! How can I help you?